MichaelBukhaloMD

PubMed

• A randomized phase 3b study evaluating the safety and efficacy of risankizumab in adult patients with moderate-to-severe plaque psoriasis with non-pustular palmoplanta...
  Mark Lebwohl, Michael Bukhalo, Linda Stein Gold, Brad Glick, Mar Llamas-Velasco
  Journal of the American Academy of Dermatology. 2024-12-01
• Efficacy and Safety of Risankizumab in Patients with Psoriasis Showing Suboptimal Response to Secukinumab or Ixekizumab: Results from a Phase 3b, Open-Label, Single-Ar...
  Richard B Warren, Lev Pavlovsky, Antonio Costanzo, Michael Bukhalo, Neil J Korman
  Dermatology and Therapy. 2024-12-01
• 5 citations
  Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
  Leon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, Michael Bukhalo, Alim R Devani
  The British Journal of Dermatology. 2023-09-15

Journal Articles

• Clinical Study Results of Desoximetasone Spray, 025% in Moderate to Severe Psoriasis  
  Kircik L, Lebwohl M, Del Rosso J, Bagel J, Gold L, Weiss J, Journal of Drugs in Dermatology, 1/1/2013
• Calcipotriene Plus Betamethasone Dipropionate Topical Suspension for the Treatment of Mild to Moderate Psoriasis Vulgaris on the body: A Randomized, Double-blind, Vehi...  
  Menter A, Gold L, Bukhalo M, Grekin S, Kempers S, Boyce B, Ganslandt C, Villumsen J, Lenwohl M, Journal of Drugs in Dermatology, 1/1/2013
• Safety and Efficacy of Multiple 16-week Courses of Topical Imiquimod for the Treatment of Large Areas of Skin Involved with Actinic Keratosis  
  Bukhalo M, The Journal of Clinical and Aesthetic Dermatology, 1/1/2009
• Photo Quiz: Red, Scaly Lesion on the Upper Eyelid  
  Altman J, Tonelli D, Bukhalo M, American Family Physician, 1/15/2007
• Role of clinical examination is screening for blunt cervical spine injury  
  Gonzales RP, Fried PO, Bukhalo M, Holevar MR, Journal of American College of Surgeons, 1/1/1999
• Join now to see all

Abstracts/Posters

• A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% Plus Betamethasone Dipropionate (BD) 0.064% is More Efficacious Than Cal and BD Foam Alone in Treating P...
  Lebwohl M, Tyring S, Bukhalo M, Alonso-Llamazares J, Oleses M, Lowson D, Yamauchi P, 73rd Annual Meeting of the American Academy of Dermatology, San Francisco, CA, 1/20/2015
• A Phase 2 Study of Photodynamic Therapy (PDT) with Aminolevulinic Acid HCI (ALA) 20% Topical Solution + Blue Light vs ALA Topical Solution Vehicle + Blue Light Using S...
  Pariser D, McConnehey D, Matheson R, Kempers S, Guenthner S, Bukhalo M, 71st Annual Meeting of the American Academy of Dermatology, Miami Beach, FL, 1/1/2013
• Randomized, Parellel-Group, Double-Blind, Vehicle-Controlled, Multicenter Phase 3 Study of the Efficacy and Safety of PEP005 (ingenol mebutate) Gel, 0.015% in Patients...
  Lebwohl M, Melgaard A, Xu Z, 22nd World Congress of Dermatology, Seoul, Korea, 1/24/2011
• Multicenter, Randomized,Parallel-Group, Double-Blind, Vehicle-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of PEP005 (ingenol) Gel 0.05% in Patients W...
  Anderson L, Melgaard A, Xu Z, 22nd World Congress of Dermatology, Seoul, Korea, 1/24/2011
• Join now to see all

Lectures

• A Novel Aerosol Foam Formulation of Calcipotriene (Cal) 0.005% Plus Betamethasone Dipropionate (BD) 0.064% is More Efficacious Than Cal and BD Foam Alone in Treating P... 
  Kaua'I, HI - 1/1/2015
• Use of Light Sources for Acne Therapy 
  St. Thomas, VI - 1/1/2009
• New Trends in Acne Therapy 
  San Antonio, TX - 1/1/2006
• LCV induced by Glyburide 
  Washington, DC - 1/1/2001
• Herpes simplex neonatorum presenting in a zosteriform distribution 
  San Francisco, CA - 1/1/1997
• Join now to see all